Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocugen

0.5564
-0.0538-8.82%
Post-market: 0.57890.0225+4.04%18:49 EDT
Volume:4.81M
Turnover:2.74M
Market Cap:162.48M
PE:-2.79
High:0.6051
Open:0.6000
Low:0.5500
Close:0.6102
Loading ...

Ocugen Inc - Phase 1/2 Study Shows Favorable Safety Profile for Ocu410

THOMSON REUTERS
·
12 Feb

Ocugen, Inc. Announces Dosing Completion in the Phase 2 Armada Clinical Trial for Ocu410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

THOMSON REUTERS
·
12 Feb

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

GlobeNewswire
·
12 Feb

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
12 Feb

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
11 Feb

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
07 Feb

Ocugen Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
05 Feb

Ocugen Says EMA Panel Issues Positive Opinion for Potential Eye Disease Treatment

MT Newswires Live
·
04 Feb

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate Ocu400 for Retinitis Pigmentosa

THOMSON REUTERS
·
03 Feb

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

GlobeNewswire
·
03 Feb

Ocugen Files Secondary Stock Shelf

MT Newswires Live
·
01 Feb

Ocugen Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
31 Jan

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
29 Jan

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
28 Jan

Ocugen announces IND in effect after FDA review

TIPRANKS
·
27 Jan

Ocugen Inc: Ocu500 Will Be Administered via Inhalation and as a Nasal Spray

THOMSON REUTERS
·
27 Jan